Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

ANBL0321 MIBG Response NCT00053326

- 20/09/21 - 1 modulo, 5 itemgroups, 6 elementi, 1 linguaggio

Itemgroups: Header, Period Number, Tumor Response, Comments, CCRR MODULE

ANBL0321 MIBG Response NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968BED1-43CF-22DE-E034-0003BA12F5E7

Ewing Study disease response VIDE DRKS00003588 NCT00824083 - Disease response VIDE Ewing Study NCT00824083

- 20/09/21 - 1 modulo, 3 itemgroups, 16 elementi, 2 lingue

Itemgroups: VIDE Response, Primary tumor, Metastasis

EWING 2008, EudraCT 2008-003658-13, http://clinicaltrials.gov/ct2/show/NCT00824083

Response - EXTENT OF DISEASE - 2411517v1.0 - EXTENT OF DISEASE

- 20/09/21 - 1 modulo, 3 itemgroups, 16 elementi, 1 linguaggio

Itemgroups: EXTENT OF DISEASE-Identification, EXTENT OF DISEASE-Evaluations, COMMENTS

Extent of Disease form for C3D 3.12 Adopters Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=01770FF7-8107-6CD5-E044-0003BA3F9857

Kidney Cancer NCT01120249 Response - Southwest Oncology Group S0931 Recurrence Assessment Form (Form #46940) - 2998562v1.0 - Southwest Oncology Group S0931 Recurrence Assessment Form (Form #46940)

- 20/09/21 - 1 modulo, 4 itemgroups, 24 elementi, 1 linguaggio

Itemgroups: Header Module, Clinical Assessment, Notice of Recurrence, COMMENTS

Southwest Oncology Group S0931 Recurrence Assessment Form (Form #46940) Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7E26385C-8CD8-C34F-E040-BB89AD434A8D

Bogen 3 Molekulares Rezidiv Progression DRKS00005243 NCT01657604 Chronic Myeloid Leukemia - Bogen 3 Molekulares Rezidiv Progression

- 17/09/21 - 1 modulo, 9 itemgroups, 30 elementi, 2 lingue

Itemgroups: Adiminstrative Daten I, Geburtsdatum, Adiminstrative Daten II, Transplantationspatient, Rezidiv, Patient ist verstorben, Patient lebt, Gründe für vorzeitiges Ausscheiden aus der Studie, Unterschrift

http://clinicaltrials.gov/ct2/show/NCT01657604

Adenocarcinoma of the Gastroesophageal Junction NCT01196390 Treatment - RTOG 1010 Post Treatment Response Form (F2) - 3180385v1.0 - RTOG 1010 Post Treatment Response Form (F2)

- 17/09/21 - 1 modulo, 3 itemgroups, 20 elementi, 1 linguaggio

Itemgroups: Header Module, Unnamed 1, Footer Module

RTOG 1010 Post Treatment Response Form (F2) Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99087049-39B3-FC29-E040-BB89AD43284B

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Week 3 - 13 and 25 - Laboratory Results; Physical Examination; Post-Treatment Response

- 30/03/21 - 1 modulo, 19 itemgroups, 62 elementi, 1 linguaggio

Itemgroups: Administrative, Laboratory Results (Week 3-13, 25) - Hematology, Laboratory Results (Week 3-13, 25) - Hematology, Laboratory Results (Week 25) - Hematology , Laboratory Results (Week 3, 13, 25) - Chemistry, Laboratory Results (Week 3 and 13) - Chemistry, Laboratory Results (Week 7) - Chemistry, Laboratory Results (Week 7) - Chemistry , Laboratory Results (Week 25) - Chemistry , Physical Examination (Week 7, 13, 25), Physical Examination (Week 7, 13, 25), Post-Treatment Response (Week 7, 13, 25) - CT or other Radiological Imaging Results, Post-Treatment Response (Week 7, 13, 25) - Bone Marrow Biopsy, Post-Treatment Response (Week 7 and 13) - Received medication/transfusion, Post-Treatment Response (Week 7, 13, 25) - Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Response, Signature of Investigator

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733 - Response Evaluation and Confirmation

- 19/02/21 - 1 modulo, 3 itemgroups, 6 elementi, 1 linguaggio

Itemgroups: Administrative Data, Response Evaluation, Complete Response Confirmation

Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. Both of these forms have to be filled out at the cycle observation visits. The Response Evaluation form also has to be filled out at possible unscheduled visits.

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Best overall response assessment; New tumor biopsy/ sample (Report Final and Annex Report 2 Final)

- 30/10/20 - 1 modulo, 3 itemgroups, 29 elementi, 1 linguaggio

Itemgroups: Administrative, Best overall response assessment, New tumor biopsy/ sample

Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Response Assessment

- 20/08/19 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio

Itemgroups: Administrative documentation, TNM clinical staging, Rectal Carcinoma, Pathological staging, Rectal Carcinoma, Sphincter, Preservation technique

Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Cisplatin and Topotecan Recurrent on Persistent Carcinoma of the Cervix - 103369 - Drug Dose Form

- 14/03/19 - 1 modulo, 6 itemgroups, 38 elementi, 1 linguaggio

Itemgroups: Administrative data, Investigational Product, Drug Dose, Tumor Measurements, Best Tumor Response, Pre-treatment Hematologies and Chemistries

Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - SRT501, Monotherapy, Cycle __ Day 21 - Physical Examination; Vital Signs; 12-Lead ECG; Hematology; Clinical Chemistry, Coagulation and Electrolytes; Urinalysis; Urinalysis microscopy results; Serum beta-hCG Pregnancy Test; Radiographic Assessment; Disease Marker Assessment; Disease Response; Study Treatment Compliance (Return); New Adverse Events and Concomitant Treatment

- 10/03/19 - 1 modulo, 23 itemgroups, 109 elementi, 1 linguaggio

Itemgroups: Administrative, Visit Date, Was a physical examination performed?, Physical Examination, Vital Signs, 12-Lead ECG, ECG Result, ECG Findings, Hematology, Hematology , Clinical Chemistry, Coagulation and Electrolytes, Clinical Chemistry, Coagulation and Electrolytes , Urinalysis dipstick results, Urinalysis microscopy results, Urinalysis microscopy results , Serum beta-hCG Pregnancy Test, Radiographic Assessment, Radiographic Assessment , Disease Marker Assessment , Disease Marker Assessment , Disease Response, Study Treatment Compliance (Return) , New Adverse Events and Concomitant Treatment

Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Keywords

Sommario

Modelli di dati selezionati